Candel Therapeutics (CADL) Assets (2020 - 2025)

Candel Therapeutics' Assets history runs 6 years deep, the most recent figure standing at $125.2 million for Q4 2025.

• In Q4 2025, Assets rose 17.15% year-over-year to $125.2 million; the TTM figure through Dec 2025 stood at $125.2 million (up 17.15% YoY), while the FY2025 annual figure was $125.2 million, up 17.15% from the prior year.
• Assets came in at $125.2 million for Q4 2025 at Candel Therapeutics, up from $93.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $125.2 million in Q4 2025 to a low of $21.5 million in Q3 2024.
• A 5-year average of $73.5 million and a median of $85.0 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets tumbled 57.02% in 2024 and soared 335.0% in 2025, its largest moves.
• Candel Therapeutics' Assets stood at $89.2 million in 2021, then slipped by 12.91% to $77.7 million in 2022, then tumbled by 46.97% to $41.2 million in 2023, then jumped by 159.38% to $106.9 million in 2024, then advanced by 17.15% to $125.2 million in 2025.
• According to Business Quant data, Assets over the past three periods registered $125.2 million, $93.6 million, and $106.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison